Cyclacel Limited
Records under this name other than the patents Cyclacel Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,133,199 | Pyrimidine derivatives as protein kinase inhibitors Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,563,542 | Pyrimidine derivatives as protein kinase inhibitors Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,592,581 | Trisubstituted purine derivatives Lapsed on the fee record Ended Nov 26, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 26, 2025 | From the USPTO record |
| US 8,536,188 | Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine Lapsed on the fee record Ended Sep 17, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 17, 2025 | From the USPTO record |
| US 8,497,291 | Crystalline pyrimidine nucleoside derivative suspensions in capsules Lapsed on the fee record Ended Jul 30, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jul 30, 2025 | From the USPTO record |
| US 9,675,631 | Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine Lapsed on the fee record Ended Jun 13, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 13, 2025 | From the USPTO record |
| US 8,404,692 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds Lapsed on the fee record Ended Mar 26, 2025 · From the USPTO record | Lapsed on the fee record | Ended Mar 26, 2025 | From the USPTO record |
| US 8,349,792 | Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent Lapsed on the fee record Ended Jan 8, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 8, 2025 | From the USPTO record |
| US 9,493,471 | Pyrimidine derivatives as protein kinase inhibitors Lapsed on the fee record Ended Nov 15, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 15, 2024 | From the USPTO record |
| US 7,582,642 | New Purine Derivatives Formerly held Term ended Ended no later than May 11, 2024 · Medium confidence | Term ended | Ended no later than May 11, 2024 | Medium confidence |